DrugPatentWatch Database Preview
Details for Patent: 6,790,459
Which drugs does patent 6,790,459 protect, and when does it expire?
This patent has fifteen patent family members in nine countries.
Summary for Patent: 6,790,459
Title: | Methods for treating diabetes via administration of controlled release metformin |
Abstract: | A method for treating patients having non-insulin-dependent diabetes mellitus (NIDDM) by administering a controlled release oral solid dosage form containing preferably a biguanide drug such as metformin, on a once-a-day basis. The dosage form provides a mean time to maximum plasma concentration (T.sub.max) of the drug which occurs at a 5.5 to 7.5 hours after oral administration on a once-a-day basis to human patients. Preferably, the dose of drug is administered at dinnertime to a patient in the fed state. |
Inventor(s): | Cheng; Xiu Xiu (Davie, FL), Chen; Chih-Ming (Davie, FL), Jan; Steve (Coral Springs, FL), Chou; Joseph (Manassas, VA) |
Assignee: | Andrx Labs, LLC (Davie, FL) |
Application Number: | 09/705,625 |
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Drugs Protected by US Patent 6,790,459
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Takeda Pharms Usa | ACTOPLUS MET XR | metformin hydrochloride; pioglitazone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 022024-001 | May 12, 2009 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN | ➤ Sign Up | ||||
Takeda Pharms Usa | ACTOPLUS MET XR | metformin hydrochloride; pioglitazone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 022024-002 | May 12, 2009 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN | ➤ Sign Up | ||||
Andrx Labs Llc | FORTAMET | metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021574-002 | Apr 27, 2004 | AB2 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION | ➤ Sign Up | |||
Andrx Labs Llc | FORTAMET | metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021574-001 | Apr 27, 2004 | AB2 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION | ➤ Sign Up | |||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
Non-Orange Book US Patents Family Members for Patent 6,790,459
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
Patent No. | Title | Estimated Patent Expiration |
---|---|---|
6,866,866 | Controlled release metformin compositions | ➤ Sign Up |
Patent No. | Title | Estimated Patent Expiration |
International Patents Family Members for US Patent 6,790,459
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
European Patent Office | 1335708 | ➤ Sign Up | |||
European Patent Office | 1723948 | ➤ Sign Up | |||
European Patent Office | 1746993 | ➤ Sign Up | |||
Australia | 2005239716 | ➤ Sign Up | |||
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |